CY2024003I2 - Ενωσεις χρησιμες ως αναστολεις κινασης - Google Patents

Ενωσεις χρησιμες ως αναστολεις κινασης

Info

Publication number
CY2024003I2
CY2024003I2 CY2024003C CY2024003C CY2024003I2 CY 2024003 I2 CY2024003 I2 CY 2024003I2 CY 2024003 C CY2024003 C CY 2024003C CY 2024003 C CY2024003 C CY 2024003C CY 2024003 I2 CY2024003 I2 CY 2024003I2
Authority
CY
Cyprus
Prior art keywords
kinase inhibitors
compounds useful
compounds
useful
kinase
Prior art date
Application number
CY2024003C
Other languages
English (en)
Other versions
CY2024003I1 (el
Original Assignee
Loxo Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology, Inc. filed Critical Loxo Oncology, Inc.
Publication of CY2024003I1 publication Critical patent/CY2024003I1/el
Publication of CY2024003I2 publication Critical patent/CY2024003I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY2024003C 2015-12-16 2024-03-04 Ενωσεις χρησιμες ως αναστολεις κινασης CY2024003I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
CY2024003I1 CY2024003I1 (el) 2024-09-20
CY2024003I2 true CY2024003I2 (el) 2024-09-20

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20201101090T CY1123561T1 (el) 2015-12-16 2020-11-16 Ενωσεις χρησιμες ως αναστολεις κινασης
CY2024003C CY2024003I2 (el) 2015-12-16 2024-03-04 Ενωσεις χρησιμες ως αναστολεις κινασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20201101090T CY1123561T1 (el) 2015-12-16 2020-11-16 Ενωσεις χρησιμες ως αναστολεις κινασης

Country Status (37)

Country Link
US (8) US10695323B2 (el)
EP (2) EP3782994B1 (el)
JP (3) JP6731483B2 (el)
KR (2) KR102215792B1 (el)
CN (9) CN114621146A (el)
AU (4) AU2016373530B2 (el)
CA (1) CA3008488C (el)
CL (1) CL2018001591A1 (el)
CO (1) CO2018006164A2 (el)
CR (1) CR20180367A (el)
CY (2) CY1123561T1 (el)
DK (1) DK3390395T3 (el)
EA (1) EA035132B1 (el)
ES (1) ES2828431T3 (el)
FI (1) FIC20240004I1 (el)
FR (1) FR24C1009I2 (el)
HR (1) HRP20201835T1 (el)
HU (2) HUE051921T2 (el)
IL (4) IL285976B2 (el)
LT (2) LT3390395T (el)
MA (2) MA55064A (el)
MD (1) MD3390395T2 (el)
MX (2) MX380907B (el)
MY (2) MY202026A (el)
NL (1) NL301262I2 (el)
NO (1) NO2024008I1 (el)
NZ (1) NZ743553A (el)
PE (3) PE20220507A1 (el)
PH (1) PH12018501268A1 (el)
PT (1) PT3390395T (el)
RS (1) RS60982B9 (el)
SG (2) SG11201805044WA (el)
SI (1) SI3390395T1 (el)
TN (1) TN2018000213A1 (el)
UA (2) UA122258C2 (el)
WO (1) WO2017103611A1 (el)
ZA (4) ZA201804137B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN108431007B (zh) 2015-09-16 2022-06-07 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
MY202026A (en) 2015-12-16 2024-03-29 Loxo Oncology Inc Compounds useful as kinase inhibitors
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
MX2020010469A (es) 2018-04-06 2021-04-19 Praxis Biotech LLC Inhibidores del atf6 y sus usos.
JP6995195B2 (ja) 2018-05-18 2022-02-04 富士フイルム株式会社 ３－ジフルオロメチルピラゾール化合物の製造方法及び３－ジフルオロメチルピラゾール－４－カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
JP7142173B2 (ja) * 2019-12-06 2022-09-26 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
BR112022013227A2 (pt) 2020-01-02 2022-09-06 Dizal Jiangsu Pharmaceutical Co Ltd Inibidores de btk
EP4118086A1 (en) * 2020-03-12 2023-01-18 Fochon Biosciences, Ltd. Compounds useful as kinase inhibitors
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
CN117320712A (zh) * 2021-05-14 2023-12-29 罗索肿瘤学公司 布鲁顿酪氨酸激酶抑制剂的共晶型
MX2024000049A (es) * 2021-07-01 2024-02-21 Hangzhou Healzen Therapeutics Co Ltd Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo.
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
JP2025500886A (ja) 2021-12-14 2025-01-15 クロスファイアー オンコロジー ホールディング ビー．ヴイ． 大環状ｂｔｋ阻害剤
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
JP2025508964A (ja) * 2022-03-03 2025-04-10 深▲チェン▼市塔吉瑞生物医薬有限公司 シクロアルキルまたはヘテロシクリルで置換されたヘテロアリール化合物、並びにその組成物及び使用
EP4493557A1 (en) * 2022-03-18 2025-01-22 Insilico Medicine IP Limited Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376B (zh) * 2022-12-15 2025-05-16 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
KR20250046558A (ko) 2023-09-27 2025-04-03 임창섭 5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
WO2025124496A1 (zh) * 2023-12-13 2025-06-19 正大天晴药业集团股份有限公司 含有吡唑环和双环杂芳基的化合物、其药物组合物及用途
WO2025137329A1 (en) * 2023-12-22 2025-06-26 Neupharma, Inc Certain chemical entities, compositions, and methods
CN119059974A (zh) * 2024-08-12 2024-12-03 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的制备方法
CN119059973A (zh) * 2024-08-12 2024-12-03 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的合成工艺
CN120504661A (zh) * 2025-07-14 2025-08-19 复旦大学 Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660744B1 (en) 1999-09-17 2003-12-09 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
PL2526934T4 (pl) 2006-09-22 2016-09-30 Inhibitory kinazy tyrozynowej Brutona
EP2068869A4 (en) * 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CA3143428A1 (en) 2007-03-28 2008-10-09 Pharmacyclics Llc 8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
CN102105459B (zh) * 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
JP6348492B2 (ja) * 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
MD20150035A2 (ro) * 2012-11-02 2015-10-31 Pfizer Inc. Inhibitori de tirozinkinaza Bruton
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
SI3052476T1 (sl) * 2013-09-30 2020-12-31 Guangzhou Innocare Pharma Tech Co., Ltd. Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
BR112016018948B1 (pt) 2014-02-21 2023-01-17 Principia Biopharma Inc Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
WO2016120196A1 (en) 2015-01-28 2016-08-04 Bayer Pharma Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108431007B (zh) 2015-09-16 2022-06-07 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
JP6728382B2 (ja) 2015-12-16 2020-07-22 エコラブ ユーエスエイ インク 膜濾過浄化のためのペルオキシギ酸組成物
CN108368086B (zh) 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物
HK1255163A1 (zh) 2015-12-16 2019-08-09 Bristol-Myers Squibb Company 作为apj受体激动剂的杂芳基羟基嘧啶酮
MY202026A (en) 2015-12-16 2024-03-29 Loxo Oncology Inc Compounds useful as kinase inhibitors
BR112018012244B1 (pt) 2015-12-16 2022-02-01 Priostar Pty Ltd Formulação, método para controlar uma praga, e, uso

Also Published As

Publication number Publication date
US20190135762A1 (en) 2019-05-09
CL2018001591A1 (es) 2018-09-28
PE20220502A1 (es) 2022-04-07
LTPA2024506I1 (el) 2024-03-25
CN114573510B (zh) 2025-02-25
CY1123561T1 (el) 2022-03-24
PE20181449A1 (es) 2018-09-12
IL281067A (en) 2021-04-29
MX2021003478A (es) 2022-07-25
ZA201804137B (en) 2022-08-31
TN2018000213A1 (en) 2019-10-04
HUS2400003I1 (hu) 2024-03-28
IL259923B (en) 2020-08-31
EA035132B1 (ru) 2020-04-30
FR24C1009I1 (fr) 2024-05-24
IL276283A (en) 2020-09-30
CN113603645B (zh) 2024-10-29
CY2024003I1 (el) 2024-09-20
PE20220507A1 (es) 2022-04-07
US20230372298A1 (en) 2023-11-23
US20200276162A1 (en) 2020-09-03
US20210093611A1 (en) 2021-04-01
LT3390395T (lt) 2020-11-25
AU2021225162A1 (en) 2021-09-30
US11471441B2 (en) 2022-10-18
AU2021225161B2 (en) 2023-08-03
JP2018538307A (ja) 2018-12-27
AU2021225162B2 (en) 2023-08-03
UA122258C2 (uk) 2020-10-12
CN113636978A (zh) 2021-11-12
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
MY202026A (en) 2024-03-29
JP2022120013A (ja) 2022-08-17
DK3390395T3 (da) 2020-09-28
CA3008488C (en) 2023-10-10
CN114634447B (zh) 2024-11-15
CN114716381B (zh) 2025-03-11
MA49809A1 (fr) 2021-08-31
ZA202107472B (en) 2023-03-29
ZA202100544B (en) 2023-06-28
JP2020172535A (ja) 2020-10-22
IL259923A (en) 2018-07-31
MA55064A (fr) 2021-09-29
KR20210018530A (ko) 2021-02-17
ES2828431T3 (es) 2021-05-26
EP3782994B1 (en) 2025-07-16
JP7419437B2 (ja) 2024-01-22
SG11201805044WA (en) 2018-07-30
CO2018006164A2 (es) 2018-09-20
CN114605327B (zh) 2025-03-11
US20220062239A1 (en) 2022-03-03
IL285976B2 (en) 2023-10-01
CN108473481B (zh) 2022-04-19
UA127863C2 (uk) 2024-01-31
MY200590A (en) 2024-01-04
WO2017103611A1 (en) 2017-06-22
KR102215792B1 (ko) 2021-02-16
MX394193B (es) 2025-03-21
CA3008488A1 (en) 2017-06-22
BR112018012341A2 (pt) 2018-12-04
US20250090500A1 (en) 2025-03-20
IL285976A (en) 2021-10-31
AU2016373530A1 (en) 2018-07-05
HUE051921T2 (hu) 2021-03-29
JP7086140B2 (ja) 2022-06-17
US10342780B2 (en) 2019-07-09
EP3390395A1 (en) 2018-10-24
SI3390395T1 (sl) 2020-11-30
US10464905B2 (en) 2019-11-05
NL301262I2 (nl) 2024-04-24
RS60982B9 (sr) 2025-07-31
CN114716381A (zh) 2022-07-08
CN114591242B (zh) 2025-01-07
US12220401B2 (en) 2025-02-11
SG10202012498TA (en) 2021-01-28
MX380907B (es) 2025-03-12
CR20180367A (es) 2018-11-12
AU2021225161A1 (en) 2021-09-30
HK1263254A1 (en) 2020-02-21
CN114591242A (zh) 2022-06-07
NZ743553A (en) 2022-08-26
FIC20240004I1 (fi) 2024-03-01
MX2018007267A (es) 2018-11-09
EP3782994A1 (en) 2021-02-24
NO2024008I1 (no) 2024-02-29
IL276283B (en) 2021-03-25
CN113603645A (zh) 2021-11-05
FR24C1009I2 (fr) 2025-02-07
CN108473481A (zh) 2018-08-31
AU2021201811B2 (en) 2022-01-27
CN114621146A (zh) 2022-06-14
ZA202107471B (en) 2023-03-29
CN114634447A (zh) 2022-06-17
KR20180115261A (ko) 2018-10-22
RS60982B1 (sr) 2020-11-30
AU2016373530B2 (en) 2021-01-21
CN113636978B (zh) 2024-10-29
EP3390395B1 (en) 2020-09-09
CN114573510A (zh) 2022-06-03
US10918622B2 (en) 2021-02-16
US20190000806A1 (en) 2019-01-03
EA201891268A1 (ru) 2018-11-30
PH12018501268A1 (en) 2019-02-18
AU2021201811A1 (en) 2021-04-22
MD3390395T2 (ro) 2021-02-28
HRP20201835T1 (hr) 2021-01-08
IL281067B (en) 2022-04-01
IL285976B1 (en) 2023-06-01
CN114605327A (zh) 2022-06-10
US11826351B2 (en) 2023-11-28
JP6731483B2 (ja) 2020-07-29
US20180362512A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
HUE057801T2 (hu) Aminotriazolopiridinek mint kináz inhibitorok
PL3209656T3 (pl) Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
ZA201700115B (en) Aminopyridazinone compounds as protein kinase inhibitors
EP3152210C0 (en) Tank-binding kinase inhibitor compounds
HUE042390T2 (hu) Heteroaril vegyületek kinázgátlásra
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
ME03610B (me) Naftiridinska jedinjenja kao inhibitori jak kinaze
HUE050842T2 (hu) Janus-kináz inhibitor
PT3298027T (pt) Compostos depsipéptidos antelmínticos
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
IL255750A (en) Heterocyclic compounds as kinase inhibitors
LT3386991T (lt) Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
HUE058802T2 (hu) RIPK1 inhibitorokként alkalmas vegyületek
LT3362444T (lt) Junginiai
DK3597189T3 (da) Krystallinske forbindelser
MA44607A (fr) Inhibiteurs de kinase
LT3331885T (lt) Junginiai
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors